Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new medication called CX11 for people with type 2 diabetes who have not achieved good blood sugar control despite taking a steady dose of metformin, with or without an SGLT2 inhibitor, for at least 90 days. This phase 2 study involves multiple medical centers and aims to determine the effectiveness and safety of CX11 compared to placebo in adults aged 18 to 75 years with specific blood sugar and body weight criteria. Participants will be randomly assigned to one of six groups, each receiving either a different dose of CX11 tablets or a matching placebo once daily. The treatment period lasts 24 weeks, followed by a 2-week safety follow-up. Neither participants nor study staff will know which group the participant is in during the study, ensuring a double-blind design. Throughout the study, participants will undergo various assessments including blood sugar measurements like HbA1c and continuous glucose monitoring, body weight and blood pressure checks, and safety monitoring for adverse events. Blood samples will be taken at multiple time points to measure drug levels. The primary outcome is the change in HbA1c after 24 weeks of treatment. Total participation lasts approximately 26 weeks, including treatment and follow-up.
Actively Recruiting
This trial is for patients with hypertension who have completed previous QCZ484 studies. It aims to gather more information on the long-term safety and effectiveness of QCZ484, a treatment given to lower high blood pressure. The study is an extension phase to build on prior research results for hypertensive patients who successfully finished earlier treatment periods. Participants in this open-label extension study will receive QCZ484 by subcutaneous injection every six months. This single-group, multicenter study offers enrollment to patients at the month 12 visit of their parent study, provided they meet eligibility and have completed their prior treatment safely. The treatment continues to be monitored for up to 66 months to assess ongoing effects and tolerability. During the study, participants will have regular assessments including ambulatory and office blood pressure measurements at baseline and throughout the extension period. Safety will be closely monitored by tracking any adverse events up to 66 months. The study collects data on blood pressure changes and side effects to understand how well QCZ484 works and how safe it remains over the long term. Participation involves scheduled visits aligned with the injection schedule and ongoing health evaluations.
Actively Recruiting
Researchers are studying the effects and safety of SPN-812 viloxazine extended release in children aged 4 to 5 years who have Attention-DeficitHyperactivity Disorder ADHD. This study is a Phase 4, randomized, double-blind, placebo-controlled trial designed to compare SPN-812 with a placebo in preschool-age children diagnosed with ADHD. The goal is to evaluate how well the medication works and how tolerable it is in this young population. Participants will be randomly assigned to receive either 100mg SPN-812 or a placebo once daily for a 6-week treatment period. Before starting treatment, children will be screened for up to 4 weeks to determine eligibility. The total study duration for each participant is up to 10 weeks, including screening and treatment. This design allows researchers to compare the effects of SPN-812 against placebo over a set timeframe. During the study, participants will be evaluated using the ADHD Rating Scale, 4th Edition, Preschool Version ADHD-RS-IV-P to measure changes in ADHD symptoms. Other assessments include the Clinical Global Impression of Severity and Change scores. Parents or guardians will provide consent, and children will be regularly monitored for safety and treatment response. Researchers will collect data at baseline and at the end of the 6-week treatment period to assess the medications impact and any side effects.
Actively Recruiting
Researchers are evaluating whether adding ABX-002 to an existing antidepressant treatment can improve depression symptoms in adults with moderate to severe major depressive disorder who have not adequately responded to their current antidepressant. This Phase 2, double-blind, placebo-controlled study aims to compare ABX-002 against a placebo alongside stable doses of selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors SSRISNRI. The study is sponsored by Autobahn Therapeutics, Inc. Participants will be randomly assigned to one of two groups one receiving ABX-002 oral solution and the other receiving a placebo, both taken as a 1-mL oral solution on an empty stomach each morning followed by water. All participants will continue their stable SSRI or SNRI antidepressant dose throughout the study. The study includes a screening period of about 35 days, a 42-day treatment period, a 2-week safety follow-up after dosing, and an additional 6-month targeted safety follow-up. During the study, participants will undergo assessments including the 17-item Hamilton Rating Scale for Depression HAMD-17 to measure changes in depression symptoms, as well as other scales like the Clinical Global Impression of Severity and Sheehan Disability Scale. Safety and tolerability will be monitored through adverse event reporting. The total participation time spans the screening through the extended safety follow-ups, with various evaluations conducted at specified intervals to track treatment effects and safety.